Postpoliomyelitis syndrome
diseaseOn this page
Also known as polio late effectsPost Polio Syndromepost-polio muscular atrophypost-polio sequelaepost-poliomyelitic syndromepostpolio sequelaepostpolio syndromepostpoliomyelitic syndromepostpoliomyelitis sequelae
Summary
Postpoliomyelitis syndrome (MONDO:0017416) is a disease and 20 clinical trials. Top therapeutic interventions include levocarnitine, modafinil, and piracetam. A subtype of poliomyelitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: Unknown (Worldwide) [Orphanet-validated]
- Phenotypes (HPO): 17
- Clinical trials: 20
Clinical features
Signs & symptoms
Clinical features (HPO)
17 HPO clinical features (Orphanet curated; top 17 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001324 | Muscle weakness | Very frequent (80-99%) |
| HP:0012531 | Pain | Very frequent (80-99%) |
| HP:0002829 | Arthralgia | Frequent (30-79%) |
| HP:0003326 | Myalgia | Frequent (30-79%) |
| HP:0003551 | Difficulty climbing stairs | Frequent (30-79%) |
| HP:0011446 | Abnormality of higher mental function | Frequent (30-79%) |
| HP:0012378 | Fatigue | Frequent (30-79%) |
| HP:0100786 | Hypersomnia | Frequent (30-79%) |
| HP:0001260 | Dysarthria | Occasional (5-29%) |
| HP:0001367 | Abnormal joint morphology | Occasional (5-29%) |
| HP:0002015 | Dysphagia | Occasional (5-29%) |
| HP:0002093 | Respiratory insufficiency | Occasional (5-29%) |
| HP:0002360 | Sleep abnormality | Occasional (5-29%) |
| HP:0002380 | Fasciculations | Occasional (5-29%) |
| HP:0003202 | Skeletal muscle atrophy | Occasional (5-29%) |
| HP:0003394 | Muscle spasm | Occasional (5-29%) |
| HP:0002791 | Hypoventilation | Very rare (<1-4%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | postpoliomyelitis syndrome |
| Mondo ID | MONDO:0017416 |
| EFO | EFO:0007454 |
| MeSH | D016262 |
| Orphanet | 2942 |
| DOID | DOID:4952 |
| ICD-10-CM | G14 |
| ICD-11 | 2018885243 |
| SNOMED CT | 31097004 |
| UMLS | C0080040 |
| MedGen | 36363 |
| GARD | 0004454 |
| NORD | 1600 |
| Is cancer (heuristic) | no |
Also known as: polio late effects · Post Polio Syndrome · post polio syndrome · post-polio muscular atrophy · post-polio sequelae · post-poliomyelitic syndrome · postpolio sequelae · postpolio syndrome · postpoliomyelitic syndrome · postpoliomyelitis sequelae · postpoliomyelitis syndrome
Disease family
This is a subtype of poliomyelitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › spinal cord disorder › myelitis › poliomyelitis › postpoliomyelitis syndrome
Related subtypes (2): paralytic poliomyelitis, acute nonparalytic poliomyelitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 6 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Human Immunoglobulin G | Phase 3 (in late-stage trials) |
| L-Citrulline | Phase 3 (in late-stage trials) |
| Levocarnitine | Phase 3 (in late-stage trials) |
| Modafinil | Phase 3 (in late-stage trials) |
| Piracetam | Phase 3 (in late-stage trials) |
| Sodium Chloride | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Poliovirus Vaccine Inactivated.
Clinical trials & evidence
Clinical trials
Clinical trials: 20.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 14 |
| PHASE3 | 4 |
| PHASE2/PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00067496 | PHASE3 | TERMINATED | Modafinil to Treat Fatigue in Post-Polio Syndrome |
| NCT00231439 | PHASE2/PHASE3 | COMPLETED | Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg) |
| NCT01537575 | PHASE3 | COMPLETED | Intravenous Immunoglobulins for Post-Polio Syndrome |
| NCT01549847 | PHASE3 | WITHDRAWN | A Randomized, Double Blind, Placebo Controlled Trial L-carnitine and Piracetam in the Treatment of Weakness, Muscle Fatigue and Muscle Pain in the Postpoliomyelitis Syndrome |
| NCT02176863 | PHASE2/PHASE3 | TERMINATED | Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% Dual Inactivation and Filtration (DIF) in Participants With Post-polio Syndrome |
| NCT02801071 | PHASE3 | COMPLETED | L-Citrulline in Patients With Post-Polio Syndrome |
| NCT02089880 | Not specified | ACTIVE_NOT_RECRUITING | Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis |
| NCT05644522 | Not specified | RECRUITING | Nomad P-KAFO Study |
| NCT05663008 | Not specified | RECRUITING | Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis |
| NCT07478172 | Not specified | RECRUITING | Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease |
| NCT00001185 | Not specified | COMPLETED | Study of Post-Polio Syndrome |
| NCT00004553 | Not specified | COMPLETED | Electromyography to Diagnose Neuromuscular Disorders |
| NCT01271530 | Not specified | COMPLETED | Arm Cycling to Improve Fitness in Polio Survivors |
| NCT01402570 | Not specified | COMPLETED | Glutathione and Health With Post-Polio Syndrome |
| NCT02815878 | Not specified | COMPLETED | Enhance Wellness for Individuals With Long-Term Physical Disabilities |
| NCT03064711 | Not specified | COMPLETED | Activity and Fatigue of the Respiratory Muscles and Pulmonary Characteristics in Post-Polio Patients |
| NCT03561623 | Not specified | UNKNOWN | Spinal Cord Gray Matter Imaging in Post Polio Syndrome |
| NCT04387864 | Not specified | COMPLETED | Whole Body Vibration on Muscle Strength in Patients With Postpolio Syndrome |
| NCT06320444 | Not specified | UNKNOWN | Non-invasive Spinal, Cortical, and Sensorimotor Biomarkers in Motor Neurone Disease |
| NCT06926270 | Not specified | COMPLETED | Effectiveness of Transcranial Magnetic Stimulation Treatment in Patients Diagnosed With Postpolio Syndrome |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LEVOCARNITINE | 4 | 1 |
| MODAFINIL | 4 | 1 |
| PIRACETAM | 4 | 1 |
| GLUTATHIONE | 3 | 1 |
| CHEMBL46909 | 0 | 1 |
Related Atlas pages
- Drugs: Levocarnitine, Modafinil, Piracetam, Glutathione